ClinicalTrials.gg
RecruitingNCT07592000Updated Aug 20, 2026

Breakthrough - T1DM and Chronic Kidney Disease

A Phase 1/2 interventional study of Tegoprubart and Islet Cell Transplant in Diabete Type 1 and Chronic Kidney Disease, sponsored by University of Chicago. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of Chicago · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Planned enrollment
728th of 819
10 · median 72
Started
2027
with 13 others
Phase 1/2
16 of 988
6 open now
Primary completion
2030-01
later than 182 of 213 live
Registered
945th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 728th largest by planned enrollment of the 819 interventional ones that give a count, is one of 14 that started in 2027, is one of 16 in phase 1/2, reaches primary completion later than 182 of the 213 other live ones, and was the 945th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

162 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

Single arm- subject treated with Tegoprubart and everolimus.

The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components:

  • An investigational drug called Tegoprubart and
  • Human pancreatic islet cells

Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years.

Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).

Read the detailed description

This study is funded by Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation) and Emerald Clinical Trials will be acting as the clinical research organization (CRO) for this study, overseeing data integrity, compliance and monitoring clinical trial activity. They will help with development of all regulatory and fully supporting University of Miami.

Islet cells are the specialized cells in the pancreas that produce insulin. In this study, islet cells will be collected from the pancreas of a deceased organ donor in a special laboratory at University of Chicago and then transplanted into the body at the University of Chicago hospital. The goal of this study is to see whether these transplanted islet cells can take over insulin production for the body. The study team will evaluate how well make insulin and how well controlled blood sugar is after the transplant. Islet transplantation has been performed and continuously optimized under clinical studies at the University of Chicago for the past 20 years. During this time, several new, potentially more effective and less toxic combinations of immunosuppressive medications have been evaluated. More recently, Tegoprubart has been tested in a small number of patients with T1D and only mild kidney dysfunction, in combination with mycophenolic acid (Myfortic). Given the promising preliminary results, Tegoprubart is now being studied in pancreatic cell transplantation together with either mycophenolic acid (MPA) or everolimus as part of the immunosuppressive regimen also in patients, who were previously ineligible for islet transplantation due to more advanced kidney dysfunction.

The islet transplant procedure involves inserting a thin, flexible tube called a catheter through a small cut in the upper abdomen. A radiologist uses x-rays and ultrasound to guide the catheter into the portal vein of the liver where the islet cells are delivered. This study of islet transplantation will test to see if islet transplantation is safe and effective; performing this study will help us find if this new medication Tegoprubart, combined with either MPA or everolimus and other medication the provider has been using routinely so far, would protect sufficiently islet transplant from the destruction by the immune system, allowing to stop insulin and have improved blood glucose control. At the same time, the providers will observe if these therapies are safe and other patients participating in the study.

Because these islet cells came from another person, the immune system may recognize them as foreign and attack them. Standard immunosuppressive medicines (Anti-thymocyte globulin [ATG] or Basiliximab and Etanercept) with either MPA or everolimus will be used to help prevent the body from attacking the transplanted islet cells. Immunosuppressive medicines may also be called anti-rejection medicines. Tegoprubart will be given in combination with these standard immunosuppressive medicines to test whether the investigational drug is safe, tolerable, and efficacious. The effect of the combination of Tegoprubart with other immunosuppressant medications has not been previously tested.

Tegoprubart is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by their immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. Tegoprubart is thought to work by dampening down our immune system so that it will be less likely to attack the transplanted cells. For other types of transplants, like kidneys, a drug called a calcineurin inhibitor is usually used to prevent rejection. That class of drugs can be toxic to islet cells. Tegoprubart is an experimental agent that is anticipated to prevent rejection without harming the islet cells. This study will test this hypothesis. Early results from a recent kidney transplant study using Tegoprubart with Myfortic show that Tegoprubart appears to be less harmful to the insulin-producing cells, the kidneys, and the nervous system compared with tacrolimus and is comparable in prevention of rejection and risk of infectious and developing blood clots in blood vessels.

The Tegoprubart for this study has been provided by Eledon Pharmaceuticals.

03

Conditions studied

  • Diabete Type 1
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible for consideration for the study only if all of the following criteria apply at the time of screening Inclusion:

  1. Subjects 18-70 years of age.
  2. A diagnosis of T1D ≥5 years with onset of disease at \<40 years of age.
  3. Ability to provide .
  4. Able to comply with study procedures, including the requirement to utilize continuous glucose monitoring (CGM).
  5. Involvement in appropriate diabetes management in accordance with the standard of care, using an insulin pump or multiple daily injection (MDI) insulin therapy and, unable to achieve acceptable metabolic control because of the occurrence of unexplained SHEs.
  6. level 6.5% to 9.5% inclusive.
  7. Absence of stimulated C-peptide (\<0.3 ng/mL) in response to a mixed- meal tolerance test (MMTT).
  8. Chronic kidney disease stage 1, 2 or 3a
  9. Impaired awareness of hypoglycemia based on:

    • IAH (HypoA-Q Impaired Awareness Subscale ≥12) and at least one level 3 SHE during the last year or
    • IAH and time-below-range (\<70 mg/dl) ≥4% with level 2 hypoglycemia (\<54 mg/dl) ≥1% (in Diabetes Care, Jan 2025, Patrick Choudhary) or
    • Clarke Score >4 or
    • Recurrent SHE defined by two or more level 3 SHEs in the year prior to screening
  10. If female, must be surgically sterile or . Women of may be enrolled if a pregnancy test is negative at screening/baseline. Women of childbearing potential and men with partners that are of childbearing potential must agree to use 2 forms of highly effective methods of from Screening, throughout the study, and while receiving therapy for the functioning graft after the conclusion of the study. Contraception use must continue for 90 days after the last administration of the study drug (see Appendix 5). Male participants must refrain from donating sperm for the duration of the study and agree to not donate sperm for 90 days after last administration of the study drug.

Exclusion Criteria:

  1. (BMI) >30 kg/m2.
  2. Weight ≤40 kg.
  3. Insulin requirement >60units/day or \<15 units/day.
  4. Untreated and uncontrolled proliferative diabetic retinopathy.
  5. Blood pressure: systolic blood pressure (SBP) >140 mmHg or diastolic blood pressure (DBP) >90 mmHg.
  6. Chronic kidney disease stage 3b or above.
  7. Diagnosis of macroalbuminuria (ACR>300 mg/g creatinine).
  8. For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 90 days after discontinuation. For male participants: intent to procreate during the duration of the study or within 90 days after discontinuation or unwillingness to use effective measures of contraception.
  9. History of except for completely resected squamous or basal cell carcinoma of the skin.
  10. History of a thromboembolic event (TE), known hypercoagulable state, or condition requiring long-term anticoagulation:

    1. Participants with a history of clotted venous access not requiring long- term anticoagulation may be included at the Principal Investigator's discretion if they have no other history of TEs or known hypercoagulable state.
    2. Patients on aspirin are allowed.
  11. Receiving treatment for a medical condition requiring chronic use of systemic , except for physiologic replacement for example in Addison disease.
  12. Presence of ongoing active infection including tuberculosis (TB), (HIV), , . Laboratory evidence of active infection even in the absence of clinical symptoms of infection is exclusionary.
  13. Invasive aspergillus, histoplasmosis or coccidioidomycosis infection within one year prior to Screening.
  14. Negative screen for Epstein-Barr Virus (EBV) by immunoglobulin G (IgG) determination.
  15. Current treatment with any immunosuppressive regimen, and treatment with biologic immune modulating agents, JAK inhibitors, S1P receptor agonists, azathioprine, 6- MP, or systemic corticosteroids.
  16. Baseline PRA over 40%
  17. Previous organ transplant (except failed pancreas or islet transplant)
  18. Persistent elevation of serum (AST) or alanine aminotransferase (ALT) value greater than 3 times the (ULN); elevation of total >1.5 ULN.
  19. Any history of receiving experimental cell or gene therapy. Exposure to any other experimental or agent within 30 days or 5 half-lives; whichever is longer.
  20. History of substance abuse within the past 6 months.
  21. Severe cardiovascular disease characterized by any one of these conditions: a) stroke; b) recent myocardial infarction (within past 6 months); c) evidence of ischemia on functional cardiac exam within the last year; d) \<30%.
  22. Significant hyperlipidemia despite medical therapy defined as fasting low-density lipoprotein (LDL) cholesterol >130 mg/dL and/ or triglycerides >200 mg/dL.
  23. Baseline below the lower limits of normal at the local laboratory; lymphopenia (\<1,000/µL), neutropenia (\<1,500/µL), or thrombocytopenia ( \<100,000/µL). Participants with lymphopenia are allowed if the Principal Investigator determines there is no additional risk and obtains clearance from a hematologist.
  24. Administration of (s) within 2 months of Screening.
  25. Any previous treatment with Tegoprubart or any other anti-0L therapy
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    TEGOPRUBART WITH EVEROLIMUS

    maintenance immunosupression consists of Tegoprubart and Everolimus

    Drug: Tegoprubart · Biological: Islet Cell Transplant

Interventions

  • Tegoprubart is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. Tegoprubart is thought to work by dampening down our immune system so that it will be less likely to attack the transplanted cells. For other types of transplants, like kidneys, a drug called a calcineurin inhibitor is usually used to prevent rejection. That class of drugs can be toxic to islet cells. Tegoprubart is an experimental agent that is anticipated to prevent rejection without harming the islet cells. This study will test this hypothesis.

  • BiologicalIslet Cell Transplant

    Human pancreatic islet cells is considered investigational because it is not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. The islet transplant procedure involves inserting a thin, flexible tube called a catheter through a small cut in the upper abdomen. A radiologist uses x-rays and ultrasound to guide the catheter into the portal vein of the liver where the islet cells are delivered. This study of islet transplantation will test to see if islet transplantation is safe and effective; performing this study will help us find if this new medication Tegoprubart, combined with either MPA or everolimus and other medication the investigators have been using routinely so far, would protect sufficiently islet transplant from the destruction by the immune system, allowing participants to stop insulin and have improved blood glucose control.

06

What researchers measure

Primary outcomes

  1. Number of participants who are achieved Optimal outcomes according to Igls criteria

    Assessed by continuous glucose monitoring (CGM) for insulin independence, HbA1c\<7.0 (53 mmol/mol), and no severe hypoglycemic episodes (SHE).

    Time frame: 1 year post-transplant

  2. Number of participants who are achieved Good outcomes according to Igls criteria

    Assessed by CGM for some insulin support, improved blood glucose control from baseline (pre-transplant), and with SHE.

    Time frame: 1 year post-transplant

Secondary outcomes

  1. Number of participants who achieved insulin independence

    Evaluated by continuous glucose monitoring.

    Time frame: 1 year post-transplant, and once a year thereafter until end of study

  2. Number of participants with no SHE and with HbA1c ≤6.5 (48 mmol/mol)

    Assessed by patient reports of SHEs and HbA1c lab value.

    Time frame: From 1 year post-transplant through end of study participation, assessed annually

  3. Number of participants with no SHE and with HbA1c ≤7.0 (53 mmol/mol)

    Assessed by patient reports of SHEs and HbA1c lab value.

    Time frame: From 1-year post-transplant through end of study participation, assessed annually

  4. Number of participants with preserved renal function (maintain the same stage of CKD)

    Measurement will be based on the stages of Chronic Kidney Disease, the investigators will check if the patient maintains the same stage, and will upgrade the stage or downgrade Stages based on eGFR.

    Time frame: From 1-year post-transplant through end of study participation, assessed annually

  5. Number of participants who developed progression of albuminuria (no albuminuria to microalbuminuria, microalbuminuria to macroalbuminuria)

    Assessed by albumin lab values in relation to pre-transplant value.

    Time frame: From 1-year post-transplant through end of study participation, assessed annually.

  6. Number of participants with no progression of albuminuria

    Assessed by albumin lab values in relation to pre-transplant value.

    Time frame: From 1-year post-transplant through end of study participation, assessed annually.

  7. Changes in estimated glomerular filtration rate (eGFR) post-transplant.

    Assessed by eGFR lab value in relation to pre-transplant value.

    Time frame: 6 months and 12 months after last islet transplant

07

Study locations

2 of 2 sites recruiting
  • Diabetes Research Institute, University of Miami
    Miami, Florida 33136, United States
    Recruiting
  • The University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Jan 2030, 33 months later.

Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
May 18, 2026
StartEst.
Apr 29, 2027
Primary completionEst.
Jan 31, 2030
CompletionEst.
Jan 31, 2030
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07592000
Collaborators
Breakthrough T1D, University of Miami
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Apr 29, 2027 (estimated)
Primary completion
Jan 31, 2030 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Aug 20, 2026

Study contacts

Alexandra Grange - Islet Cell Transplant Program Manager
Contact
Alexandra.Grange@bsd.uchicago.edu
773-702-9771
Minelly Escobedo
Contact
Minelly.Escobedo@bsd.uchicago.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion